Premium
Janus kinase inhibitors for inflammatory bowel disease
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1732
Subject(s) - tofacitinib , medicine , ulcerative colitis , inflammatory bowel disease , janus kinase , janus kinase inhibitor , crohn's disease , disease , gastroenterology , rheumatoid arthritis , cytokine
NICE recently recommended the janus kinase (JAK) inhibitor tofacitinib (Xeljanz) for second‐line treatment of moderately to severely active ulcerative colitis. This article summarises the efficacy for tofacitinib in inflammatory bowel disease (ulcerative colitis and Crohn's disease), and discusses a new JAK inhibitor, filgotinib, that has shown promise in Crohn's disease.